33
Views
8
CrossRef citations to date
0
Altmetric
Article

Changes in bone mineral density differ between gonadotrophin‐releasing hormone analogue‐ and surgically castrated men with prostate cancer
A prospective, controlled, parallel‐group study

, , &
Pages 148-152 | Received 08 Nov 2002, Accepted 24 Jun 2003, Published online: 09 Jul 2009

References

  • Johansson J-E, Hellstrom M, Gustafsson 0, Stattin P. Hellström K, Nilsson J, et al. The register of prostatic cancer in Sweden 1996–1999. May 2001 ROC, Uppsala, Sweden.
  • Helgesen F, Holmberg L, Johansson JE, Bergstrom R, Adami HO. Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of non-lethal tumours. J Natl Cancer Inst 1996; 88: 1216–21.
  • Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–7.
  • Henriksson P. Edhag 0. Cost-effectiveness comparison of oestrogen therapy and orchidectomy in patients with prostatic cancer. Int J Technol Assess Health Care 1987; 3: 523–9.
  • Kaisary AV, Tyrell CJ, Peeling WB, Griffiths K. Com-parison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502–8.
  • Johansson J-E, Andersson S-0, Holmberg L, Bergstrom L. Primary orchiectomy versus estrogen therapy in advanced prostatic cancer-a randomized study: results after 7-10 years followup. J Urol 1991; 145: 519–23.
  • Boccon-Gibod L, Fournier G, Bottet P. Marechal JM, Guiter J, Rischman P. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997; 32: 391–5.
  • Crawford ED, Eisenberg MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–24.
  • Murphy S, Khaw K, Cassidy A, Compston JE. Sex hormones and bone mineral density in elderly men. Bone Miner 1993; 20: 133–40.
  • Kanis JA, Melton III J, Christiansen C, Johnston C, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137–41.
  • Perry III HM, Morley JE. Osteoporosis in men: are we ready to diagnose and treat? Curr Rheumatol 2001; 3: 240–4.
  • Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002; 87: 589–98.
  • Summers GD. Osteoporosis in men. Radiography 2001; 7: 11923.
  • Pande I, Frances RM. Osteoporosis in men. Best Pract Res Clin Rheumatol 2001; 15: 415–29.
  • Davidson CW, Merrilees MJ, Wilkinson TJ, McKie JS, Gilchrist NL. Hip fracture mortality and morbidity-can we do better? N Z Med J 2001; 114: 329–32.
  • Diamond T, Sambrook P, Williamson M, Flicker L, Nowson C, Fiatarone-Singh M, et al. Men and osteo-porosis. Aust Fam Physician 2001; 8: 781–5.
  • Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989; 69: 523–7.
  • Eriksson S, Eriksson A, Stege R, Carlström K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1994; 57: 97–9.
  • Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A. Bone loss in men with prostate cancer treated with gonadotropine releasing hormone agonists. J Clin Endocrinol Metab 2001; 86: 2787–91.
  • Kiralti BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57: 127–32.
  • Daniell HVV, Dunn SR, Ferguson DW, Lomas G, Niaszi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181–6.
  • Townsend MF, Holt Sanders W, Northway RO, Graham SD. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997; 79: 545–9.
  • Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439–44.
  • Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Gold-man H, Resnick M. Skeletal fractures associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166: 1724–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.